Diagnosis and treatment of thrombotic microangiopathy

65Citations
Citations of this article
109Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. TMAs have varying underlying pathophysiology and can therefore present with an array of clinical presentations. Renal involvement is common as the kidney is particularly susceptible to the endothelial damage and microvascular occlusion. TMAs require rapid assessment, diagnosis, and commencement of appropriate treatment due to the high morbidity and mortality associated with them. Ground-breaking research into the pathogenesis of TMAs over the past 20 years has driven the successful development of targeted therapeutics revolutionizing patient outcomes. This review outlines the clinical presentations, pathogenesis, diagnostic tests and treatments for TMAs.

Cite

CITATION STYLE

APA

Thompson, G. L., & Kavanagh, D. (2022, September 1). Diagnosis and treatment of thrombotic microangiopathy. International Journal of Laboratory Hematology. John Wiley and Sons Inc. https://doi.org/10.1111/ijlh.13954

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free